United States
Theromics Inc. is a biotechnology startup founded in 2016 in the United States that focuses on revolutionizing thermal ablation procedures for soft tissue and drug delivery. The company's Theromics HeatSYNC Technology aims to enhance thermal ablations of soft tissue by combining them with drug delivery.
Theromics has developed a novel, safe Thermal Accelerant designed for use during microwave, RFA, or cryoablation procedures. This HeatSYNC innovation can extend the reach of thermal energy beyond the capabilities of microwave or radiofrequency devices without requiring high-power energy. Furthermore, the gel is being researched as a potential drug delivery system combined with thermal ablation, introducing a new therapy known as TACT - Thermally Activated Combination Therapy.
It's worth noting that the device for Investigational Use Only and has not yet been cleared by the FDA or other regulatory bodies.
The company secured a $1.00M grant investment on 12 March 2024 from the National Science Foundation.
-logo.jpg "Clinical Laserthermia Systems AB (CLSB)"){kind=logo}